Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

BACKGROUND The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been unde...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2018-09, Vol.124 (17), p.3520-3527
Main Authors: Brand, Randall, Borazanci, Erkut, Speare, Virginia, Dudley, Beth, Karloski, Eve, Peters, Mary Linton B., Stobie, Lindsey, Bahary, Nathan, Zeh, Herbert, Zureikat, Amer, Hogg, Melissa, Lee, Kenneth, Tsung, Allan, Rhee, John, Ohr, James, Sun, Weijing, Lee, James, Moser, A. James, DeLeonardis, Kim, Krejdovsky, Jill, Dalton, Emily, LaDuca, Holly, Dolinsky, Jill, Colvin, Arlene, Lim, Cynthia, Black, Mary Helen, Tung, Nadine
Format: Article
Language:English
Subjects:
Adenocarcinoma
Demographics
Demography
Deoxyribonucleic acid
DNA
Genes
Genetic screening
genetic susceptibility
Genetic testing
germline mutation
Health risk assessment
Health risks
hereditary cancer syndromes
Mutation
Oncology
Pancreas
Pancreatic cancer
pancreatic ductal adenocarcinoma
Patients
Population genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3‐generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7%), with 23 (7.7%) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26%) with PDAC‐associated gene mutations did not meet currently established genetic testing criteria. According to guideline‐based genetic testing, only 11 of the 23 PGVs (48%) in known PDAC genes would have been detected. Six additional patients (2%) had PGVs associated with an increased risk for other cancers. CONCLUSIONS These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population. This study suggests that a substantial proportion of pancreatic cancer cases may be explained by mutations in cancer susceptibility genes and points to limitations of genetic testing criteria in identifying genetic risk for this disease. These findings lend support for universal germline genetic testing in patients with pancreatic cancer.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.31628